Physician profile
Edward Oruci
NPI 1619955499
$15,906.20
in general payments reported to CMS, 2019-2025
38 companies · $2,354 in 2025
The $2,354 reported for 2025 was more than what 95% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,925 · 2020: $1,686 · 2021: $2,515 · 2022: $2,983 · 2023: $2,064 · 2024: $2,380 · 2025: $2,354.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,797.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,797.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,732.05 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $1,654.40 | 2019-2025 | |
| Medtronic, INC. | $1,277.03 | 2021-2025 | Symplicity G3, Onyx Frontier |
| Astrazeneca Pharmaceuticals LP | $1,196.33 | 2019-2025 | Farxiga, Wainua |
| Janssen Pharmaceuticals, INC | $835.64 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $831.29 | 2021-2025 | Verquvo, Capvaxive |
| Pfizer INC. | $794.69 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $784.06 | 2019-2025 | Jardiance |
| Esperion Therapeutics, INC. | $721.16 | 2020-2025 | Nexletol |
| E.R. Squibb & Sons, L.L.C. | $716.96 | 2019-2025 | Eliquis, Camzyos |
| Abbott Laboratories | $601.57 | 2019-2025 | Aveir, Gallant, Mitraclip |
| Medtronic Vascular, INC. | $565.16 | 2019-2020 | |
| Novo Nordisk INC | $525.53 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $481.06 | 2022-2025 | |
| Boston Scientific Corporation | $434.68 | 2020-2025 | Watchman Flx, Cds - Mct/Cem Monitoring, Watchman Access System |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $327.27 | 2019-2024 | |
| Cvrx, INC. | $256.94 | 2024-2025 | Barostim Neo System |
| Arbor Pharmaceuticals, INC. | $239.92 | 2019-2021 | |
| Lexicon Pharmaceuticals, INC. | $227.09 | 2023-2024 | Inpefa |
| Daiichi Sankyo INC. | $225.22 | 2024-2025 | Injectafer |
| Chiesi USA, INC. | $224.04 | 2019-2024 | Kengreal, Cleviprex |
| Althera Pharmaceuticals LLC | $194.59 | 2021-2022 | |
| Heartflow, INC. | $138.86 | 2024-2025 | |
| Kowa Pharmaceuticals America, INC. | $133.65 | 2019-2023 | Livalo |
| Regeneron Healthcare Solutions, INC. | $114.48 | 2019-2024 | Evkeeza, Praluent |
| Kestra Medical Technology Services, INC. | $109.45 | 2022-2023 | Assure Wcd |
| Scpharmaceuticals INC. | $89.32 | 2023-2025 | |
| Inspire Medical Systems, INC. | $78.66 | 2023-2025 | Inspire |
| Kiniksa Pharmaceuticals, LTD. | $76.23 | 2023 | Arcalyst |
| Lundbeck LLC | $47.19 | 2019 | |
| Glaxosmithkline, LLC. | $45.80 | 2025 | Arexvy, Shingrix |
| Csl Behring | $45.30 | 2020 | |
| Impulse Dynamics (USA) INC. | $41.31 | 2021-2022 | |
| Kiniksa Pharmaceuticals International, Plc | $40.48 | 2024 | Arcalyst |
| Cumberland Pharmaceuticals, INC. | $35.62 | 2023-2024 | Caldolor |
| Astellas Pharma US INC | $30.37 | 2019-2020 | |
| Lilly USA, LLC | $19.22 | 2025 | Zepbound |
| Gilead Sciences, INC. | $13.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Oruci listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.